Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454-464.
Stone RM, Mandrekar SJ, Sanford BL, et al. The addition of midostaurin to standard chemotherapy decreases cumulative incidence of relapse (CIR) in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603 / RATIFY [alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations [ASH abstract 2580]. Blood. 2017;130(suppl 1):2580.
Larson RA, Mandrekar SJ, Sanford BL, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 145.
Schmalbrock LK, Cocciardi S, Dolnik A, et al. Clonal evolution of FLT3-ITD positive AML in patients treated with midostaurin in combination with chemotherapy within the RATIFY (CALGB 10603) and AMLSG 16-10 trials [ASH abstract 182]. Blood. 2017;130(suppl 1):182.
Döhner K, Thiede C, Larson RA, et al. Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients with acute myeloid leukemia (AML) treated within the international RATIFY study. Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 467.
Pollyea DA, Tallman MS, De Botton S, et al. Enasidenib monotherapy is effective and well-tolerated in patients with previously untreated mutant-IDH2 (mIDH2) acute myeloid leukemia (AML). Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 638.
DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015. 90:732-736.
FDA granted regular approval to enasidenib for the treatment of relapsed or refractory AML. US Food and Drug Administration website. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569482.htm. Updated August 1, 2017. Accessed January 15, 2018.
DiNardo CD, De Botton S, Stein EM, et al. Ivosidenib (AG-120) in mutant IDH1 AML and advanced hematologic malignancies: results of a phase 1 dose escalation and expansion study. Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 725.
Stone RM, Choe S, Zhang V, et al. Genetic profiling and deep IDH1 mutation clearance to ≤0.04% in ivosidenib (AG-120)-treated patients with mutant IDH1 relapsed or refractory and untreated AML [ASH abstract 2684]. Blood. 2017;130(suppl 1):2684.
DiNardo CD, Stein AS, Fathi AT, et al. Mutant isocitrate dehydrogenase (mIDH) inhibitors, enasidenib or ivosidenib, in combination with azacitidine (AZA): preliminary results of a phase 1b/2 study in patients with newly diagnosed acute myeloid leukemia (AML). Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 639.
Stein EM, DiNardo CD, Mims AS, et al. Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: initial results from a phase 1 trial. Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 726.
Zeidan AM, Cook RJ, Bordoni R, et al. A phase 1/2 study of the oral novel JAK1 inhibitor INCB052793 as monotherapy and in combination with standard therapies in patients with advanced hematologic malignancies [ASH abstract 640]. Blood. 2017;130(suppl 1):640.
Daver N, Pollyea DA, Yee KWL, et al. Preliminary results from a phase Ib study evaluating BCL-2 inhibitor venetoclax in combination with MEK inhibitor cobimetinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory (R/R) AML [ASH abstract 813]. Blood. 2017;130(suppl 1):813.
Uy GL, Godwin J, Rettig MP, et al. Preliminary results of a phase 1 study of flotetuzumab, a CD123 x CD3 bispecific DART® protein, in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome [ASH abstract 637]. Blood. 2017;130(suppl 1):637.
DeAngelo DJ, Jonas BA, Liesveld JL, et al. GMI-1271 improves efficacy and safety of chemotherapy in R/R and newly diagnosed older patients with AML: results of a phase 1/2 study [ASH abstract 894]. Blood. 2017;130(suppl 1):894.
Mateos MV, Lopez JM, Rodriguez-Otero P, et al. Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with KRd and maintenance with Rd. Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 402.
Mateos MV, Dimopoulos MA, Cavo M, et al. Phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in newly diagnosed multiple myeloma (NDMM) patients (pts) ineligible for transplant (ALCYONE). Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract LBA-4.
Mateos MV, Goldschmidt H, San Miguel JF, et al. Relapsed or refractory multiple myeloma patients treated with second-line carfilzomib and categorized by prior exposure to bortezomib: a subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials [ASH abstract 1840]. Blood. 2017;130(suppl 1):1840.
Mateos MV, Goldschmidt H, San Miguel JF, et al. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: a subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials [ASH abstract 3120]. Blood. 2017;130(suppl 1):3120.
Niesvizky R, Ludwig H, Spencer A, et al. Overall survival of relapsed/refractory multiple myeloma patients treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone: results from the phase 3 ENDEAVOR study according to age subgroup [ASH abstract 1885]. Blood. 2017;130(suppl 1):1885.
Clinicaltrials.gov. Lenalidomide/bortezomib/dexamethasone for multiple myeloma (MM) (RVD lite). https://clinicaltrials.gov/ct2/show/NCT01782963. Accessed January 15, 2018.
O'Donnell E, Laubach J, Yee AJ, et al. Final results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (RVD lite) in transplant-ineligible multiple myeloma [ASH abstract 3126]. Blood. 2017;130(suppl 1):3126.
Jakubowiak AJ, Raje N, Vij R, et al. High rate of sustained minimal residual disease negativity predicts prolonged survival for the overall patient population in the phase 2 KRd plus autologous stem cell transplantation MMRC trial [ASH abstract 4533]. Blood. 2017;130(suppl 1):4533.
Berdeja JG, Lin Y, Raje N, et al. Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-BCMA CAR T cell therapy. Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 740.
Joseph N, Almaula D, Gleason C, et al. Lenalidomide, bortezomib, and dexamethasone (RVD) as induction therapy in newly diagnosed multiple myeloma (MM) [ASH abstract 3139]. Blood. 2017;130(suppl 1):3139.
Siegel D, Schiller GJ, Samaras C, et al. Safety and efficacy of pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) as second- or third-line therapy in patients with relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure [ASH abstract 1811]. Blood. 2017;130(suppl 1):1811.
Nooka AK, Joseph N, Boise LH, et al. Clinical efficacy of daratumumab, pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among refractory patients. Paper presented at: 2016 Meeting of the American Society of Hematology; December 3-6, 2016; San Diego, CA. Abstract 492.
Lonial S, San Miguel JF, Martinez-Lopez J, et al. Daratumumab in combination with carfilzomib and dexamethasone in patients (pts) with relapsed multiple myeloma (MMY1001): an open-label, phase 1b study [ASH abstract 1869]. Blood. 2017;130(suppl 1):1869.
GisslingerH, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized controlled trial [ASH abstract 320]. Blood. 2017;130(suppl 1):320.
Yacoub A, Mascarenhas J, Kosiorek HE, et al. Single-arm salvage therapy with pegylated interferon alfa-2a for patients with high-risk polycythemia vera or high-risk essential thrombocythemia who are either hydroxyurea-resistant or intolerant: final results of the myeloproliferative disorders-research consortium (MPD-RC) protocol 111 global phase II trial [ASH abstract 321]. Blood. 2017;130(suppl 1):321.
Bose P, Daver N, Pemmaraju N, et al. Sotatercept (ACE-011) alone and in combination with ruxolitinib in patients (pts) with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and anemia [ASH abstract 255]. Blood. 2017;130(suppl 1):255.
Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641-3649.
Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123:3239-3246.
Lancet JE, Uy GL, Cortes JE, et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. Paper presented at: 2016 Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 7000.
Lancet JE, Ritchie EK, Uy GL, et al. Efficacy and safety of CPX-351 versus 7+3 in older adults with secondary acute myeloid leukemia: combined subgroup analysis of phase 2 and phase 3 studies [ASH abstract 2657]. Blood. 2017;130(suppl 1):2657.
Cavo M, Hájek R, Pantani L, et al. Autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMN02/HO95 study. Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 397.
Goldschmidt H, Mai EK, Dürig J, et al. Response-adapted lenalidomide maintenance in newly diagnosed, transplant-eligible multiple myeloma: results from the multicenter phase III GMMG-MM5 trial. Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 400.
Clinicaltrials.gov. Bortezomib or carfilzomib with lenalidomide and dexamethasone in treating patients with newly diagnosed multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT01863550. Accessed January 15, 2018.
Jackson G, Davies FE, Pawlyn C, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma XI trial. Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 436.
Hofmeister CC, Chari A, Cohen Y, et al. Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): CENTAURUS, a randomized, open-label, multicenter phase 2 study. Paper presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 510.
White DJ, Bahlis NJ, Venner CP, et al. A phase Ib/II trial of selinexor combined with lenalidomide and low dose dexamethasone in patients with relapsed/refractory multiple myeloma. Poster presented at: 2017 Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA. Abstract 1861.

CME / ABIM MOC / CE

Updates on Multiple Myeloma and MPNs: Findings From the 2017 Hematology Conference

Authors: Richard Stone, MD; Maria-Victoria Mateos, MD, PhD; Noopur Raje, MD; Sagar Lonial, MD; Ruben Mesa, MD; Vincent Rajkumar, MD
CME / ABIM MOC / CE Released: 12/28/2017
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 12/28/2018

Target Audience and Goal Statement

This activity is intended for hematologists, oncologists, pathologists, emergency medicine physicians, pharmacists, and nurses.

The goal of this activity is to provide education on recently reported study findings on multiple myeloma (MM) and myeloproliferative neoplasms.

Upon completion of this activity, participants will have increased knowledge regarding the:

Most significant findings from clinical trials evaluating treatment strategies for MM or myeloid malignancies presented at the 2017 annual hematology meeting
Strategies for integrating new data about the management of MM or myeloid malignancies presented at the 2017 annual hematology meeting into clinical practice to improve care for patients

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Richard Stone, MD

Professor of Medicine, Harvard Medical School; Director, Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Disclosures

Disclosure: Richard M. Stone, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie, Inc.; Agios Pharmaceuticals; Amgen Inc.; Celator/Jazz Pharmaceuticals; Celgene Corporation; FujiFilm; Janssen Pharmaceuticals, Inc; Juno Therapeutics, Inc.; Karyopharm Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Seattle Genetics
Other: Data Safety Monitoring Board for Celgene Corporation

Dr Stone does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Stone does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Faculty

Maria-Victoria Mateos, MD, PhD

Professor, University Hospital of Salamanca, Salamanca, Spain

Disclosures

Disclosure: Maria-Victoria Mateos, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.

Dr Mateos does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Mateos does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Noopur Raje, MD

Professor of Medicine, Harvard Medical School; Clinical Director, Center for Myeloma, Massachusetts General Hospital, Boston, Massachusetts, United States

Disclosures

Disclosure: Noopur Raje, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Roche; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP

Dr Raje does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Raje does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Sagar Lonial, MD

Professor and Chair of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States

Disclosures

The opinions expressed are those of Dr. Lonial and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr. Lonial’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Disclosure: Sagar Lonial, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals North America, Inc.

Dr Lonial does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Lonial does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Ruben Mesa, MD

Director, UT Health San Antonio Cancer Center, San Antonio, Texas, United States

Disclosures

Disclosure: Ruben Mesa, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AOP Orphan Pharmaceuticals AG; Novartis Pharmaceuticals Corporation; Shire
Received grants for clinical research from: CTI BioPharma Corp.; Gilead Sciences, Inc.; Incyte Corporation; Promedior, Inc.

Dr Mesa does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Mesa does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps Professor of Medicine, Mayo Clinic, Rochester, Minnesota, United States

Disclosures

Disclosure: Vincent Rajkumar, MD, has disclosed no relevant financial relationships.

Dr Rajkumar does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Rajkumar does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Vandana Iyer, PhD

Associate Scientific Director, Medscape, LLC

Disclosures

Disclosure: Vandana Iyer, PhD, has disclosed no relevant financial relationships.

Davecia R. Cameron, MS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

Charlotte Warren

Senior Scientific Director, Medscape, LLC

Disclosures

Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

Sarah Williams, PhD

Lead Scientific Director, Medscape, LLC

Disclosures

Disclosure: Sarah Williams, PhD, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.75 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.75 contact hour(s) (0.0.75 CEUs) (Universal Activity Number: 0461-0000-17-206-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

The Nurse View: A Clinical Resource for Oncology Nurses

From Medscape Education Oncology

CME / ABIM MOC / CE

Updates on Multiple Myeloma and MPNs: Findings From the 2017 Hematology Conference

Authors: Richard Stone, MD; Maria-Victoria Mateos, MD, PhD; Noopur Raje, MD; Sagar Lonial, MD; Ruben Mesa, MD; Vincent Rajkumar, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 12/28/2017

Valid for credit through: 12/28/2018

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

CME / ABIM MOC / CE Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Richard Stone, MD

Faculty

Maria-Victoria Mateos, MD, PhD

Noopur Raje, MD

Sagar Lonial, MD

Ruben Mesa, MD

Vincent Rajkumar, MD

Editor

Vandana Iyer, PhD

Davecia R. Cameron, MS

Charlotte Warren

Sarah Williams, PhD

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

CME / ABIM MOC / CE

Updates on Multiple Myeloma and MPNs: Findings From the 2017 Hematology Conference

Target Audience and Goal Statement

Disclosures

Moderator

Richard Stone, MD

Faculty

Maria-Victoria Mateos, MD, PhD

Noopur Raje, MD

Sagar Lonial, MD

Ruben Mesa, MD

Vincent Rajkumar, MD

Editor

Vandana Iyer, PhD

Davecia R. Cameron, MS

Charlotte Warren

Sarah Williams, PhD

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Updates on Multiple Myeloma and MPNs: Findings From the 2017 Hematology Conference